Sun Pharma & Bayer tie up to market new renal therapy – Times of India
[ad_1] Sun Pharma and Bayer announced that they have signed an agreement to market and distribute a second brand of Finerenone in India. Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic…